



DIVISION OF  
CORPORATION FINANCE

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

July 19, 2024

Artiva Biotherapeutics, Inc.  
5505 Morehouse Drive, Suite 100  
San Diego, CA 92121

**Re: Artiva Biotherapeutics, Inc.**  
**Amendment No. 1 to Registration Statement on Form S-1**  
**Exhibit Nos. 10.13, 10.16, 10.18 10.19, 10.20, 10.21, 10.25 and 10.26**  
**Filed July 15, 2024**  
**File No. 333-280568**

Dear Fred Aslan:

We have concluded our assessment of your redacted exhibits for compliance with applicable form requirements and will process your supplemental response and related materials in accordance with your request.

Sincerely,

Division of Corporation Finance  
Office of Life Sciences